Zantac OTC Recall: Sanofi Voluntarily Recalls All Zantac OTC in the U.S.
On October 18, 2019, Sanofi reportedly announced that it was voluntarily issuing a recall of all Zantac OTC (over-the-counter) oral heartburn, sour stomach and acid indigestion tablets in the United States, including the following tablets:
- Zantac 150®
- Zantac 150® Cool Mint
- Zantac 75®
Zantac is the brand name of generic medication known as ranitidine.
The FDA had earlier issued a statement alerting the public that some ranitidine medicines such as Zantac OTC could contain NDMA which has been classified as a probable human carcinogen (i.e., a substance that could cause cancer) based on results from laboratory tests.
If you took recalled Zantac 150, Zantac 150 Cool Mint, Zantac 75 (Zantac OTC Products) and were diagnosed with cancer, you may be able to seek compensation from a Zantac recall lawsuit.
If You Have Thoughts On The Zantac 150, Zantac 150 Cool Mint or Zantac 75 OTC Recall, Share Your Comments Below.